Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged 12–17, according to a news release from the manufacturer.
The DELTA TEEN trial was a 16-week, randomized, double-blind, vehicle-controlled study that included adolescents for whom topical corticosteroids were inadequate or inappropriate. According to the most recent results, the trial achieved its primary endpoint with statistical significance vs. cream vehicle. The safety profile was consistent with earlier pivotal studies. Detailed trial results, according to the press release, will be presented at a future scientific forum. The manufacturer added that these findings expand the scope of Anzupgo.
"Research on adolescents with CHE has revealed that the condition can considerably affect their quality of life, including psychosocial well-being, school performance, and leisure activities," said Professor Sonja Molin, coordinating investigator of the study, in the news release. "These findings further our understanding of how moderate to severe CHE manifests in adolescents and how to support this underserved patient group."
Source: Leo Pharma press release. Feb 4, 2025.